No Data
No Data
Sunshine Guojian Pharmaceutical (688336.SH) will have approximately 524 million restricted shares available for public trading starting from July 22nd.
Sunshine Guojian Pharmaceutical (688336.SH) announced that the restricted stocks to be listed and circulated this time are the initial restricted stocks of the company, which are restricted from sale...
Sunshine Guojian Pharmaceutical was awarded the A-share ESG Value Award of China Listed Companies English and Chinese by 2024.
Shanghai, July 11, 2024 / PRNewswire / - The 2024 China Capital Market Development Forum and Listing Company Forum, sponsored by China Fund News, was recently held in Shanghai. The forum also announced the winners of the 2024 China Listed Company Yinghua Demonstration Case Awards. Sunshine Guojian Pharmaceutical, a leader in innovative antibody drug development in China, won the A-share ESG Value Award. The China Listed Company Yinghua Demonstration Case Awards, initiated by China Fund News, aims to adhere to the spirit of the new "Nine Articles of the State," evaluate the comprehensive strength and value of the enterprise from a long-term and value investment perspective, and select the institutions that invest in them.
Sunshine Guojian Pharmaceutical (688336.SH) plans to distribute 0.05 yuan per share in 2023, with ex-rights and ex-dividends on June 26th.
Sunshine Guojian Pharmaceutical (688336.SH) announced that it plans to distribute a cash dividend of 0.05 yuan per share for the year 2023.
Sunshine Guojian Pharmaceutical (688336.SH) plans to launch a restricted stock incentive plan in 2024 with a grant price of 12.00 yuan/share.
Sunshine Guojian Pharmaceutical (688336.SH) released its restricted stock incentive plan (draft) for 2024. This incentive plan...
Sunshine Guojian Pharmaceutical (688336.SH): Intends to sign an exclusive license agreement with Shenyang Sunshine.
Sunshine Guojian Pharmaceutical (688336.SH) announced on June 5th that the company plans to sign an exclusive license agreement with Shenyang Sunshine, granting Shenyang Sunshine exclusive rights to the company's 706, 709, HBT-2002, QY-F10, QY-F11, QY-F07, and QY-F02 projects in the licensed area (Greater China) for the research and development, registration, improvement, production, use, sale, and promise to sell licensed products against collaborative targets for all approved indications, as well as use other intellectual property licensed by Sunshine Guojian Pharmaceutical to Shenyang Sunshine.
Here's Why We Think Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Unfortunately, these high risk investment
No Data